The results of a new clinical trial with ketamine were published in Nature’s Molecular Psychiatry journal. Researchers conducted a double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). 99 subjects, 18-70 years old with TRD…
The National Institute of Mental Health (NIMH) issued a highlight on ketamine for treating depression. The most commonly used antidepressants are largely variations on a theme; they increase the supply within synapses of a class of neurotransmitters believed to play a…
Researchers from the University of Minnesota and The Mayo Clinic found that ketamine caused an average decrease of 42% on the Children’s Depression Rating Scale(CDRS)—the most widely used rating scale in research trials for assessing the severity of depression and…
Researchers at Yale published a new study titled “Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital” in Clinical Psychiatry. In late 2014, Yale began providing ketamine as an off-label therapy on a case-by-case…
CNN featured a segment on the use of ketamine for treating suicidal ideation–a novel, off-label use for ketamine that is currently being explored in human clinical trials. The segment featured Dr. Sanjay Gupta sharing the story of Alan Ferguson. Mr….
Neuropathic pain is notoriously difficult to treat. Patients are often treated as regular chronic pain patients and many resort to opioids to manage extreme levels of pain. Neuropathic pain can originate from infection, metabolic diseases, chemotherapy, trauma and many other…
PTSD Treatment – Ketamine is a novel treatment for several psychiatric disorders including: Major Depressive Disorder, Bipolar Depression, Postpartum Depression, Obsessive-Compulsive Disorder (OCD), and Posttraumatic Stress Disorder or PTSD. It was originally FDA approved for anesthesia but is now frequently...
Good news for patients suffering from Chronic Migraine or new daily persistent headache. A retrospective review of 77 patients who underwent administration of intravenous, subanesthetic ketamine was conducted by investigators at Thomas Jefferson University. Their results were just published in…
Double-Blind Clinical Trial Shows that Dose Matters with Ketamine in Depressed Patients
The results of a new clinical trial with ketamine were published in Nature’s Molecular Psychiatry journal. Researchers conducted a double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). 99 subjects, 18-70 years old with TRD…
The National Institute of Mental Health Highlights Ketamine for Depression
The National Institute of Mental Health (NIMH) issued a highlight on ketamine for treating depression. The most commonly used antidepressants are largely variations on a theme; they increase the supply within synapses of a class of neurotransmitters believed to play a…
IV Ketamine Shows Promise in Clinical Trial with Depressed Teens
Researchers from the University of Minnesota and The Mayo Clinic found that ketamine caused an average decrease of 42% on the Children’s Depression Rating Scale(CDRS)—the most widely used rating scale in research trials for assessing the severity of depression and…
Yale study found no safety issues with long-term ketamine treatment
Researchers at Yale published a new study titled “Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital” in Clinical Psychiatry. In late 2014, Yale began providing ketamine as an off-label therapy on a case-by-case…
CNN Reports ‘Ketamine offers lifeline for suicidal thoughts’
CNN featured a segment on the use of ketamine for treating suicidal ideation–a novel, off-label use for ketamine that is currently being explored in human clinical trials. The segment featured Dr. Sanjay Gupta sharing the story of Alan Ferguson. Mr….
Ketamine alone beats methadone and methadone/ketamine combo for neuropathic pain
Neuropathic pain is notoriously difficult to treat. Patients are often treated as regular chronic pain patients and many resort to opioids to manage extreme levels of pain. Neuropathic pain can originate from infection, metabolic diseases, chemotherapy, trauma and many other…
Ketamine is a new, faster option for treating PTSD
New study confirms IV ketamine is efficacious for treatment refractory headache
Good news for patients suffering from Chronic Migraine or new daily persistent headache. A retrospective review of 77 patients who underwent administration of intravenous, subanesthetic ketamine was conducted by investigators at Thomas Jefferson University. Their results were just published in…